SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors induce glycosuria and natriuresis by inhibiting sodium and glucose reabsorption, leading to improved glycemic control, small reduction in blood pressure, and mild to modest weight loss among patients with type 2 diabetes [12, 13].